{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:12:00Z","timestamp":1785510720670,"version":"3.56.0"},"reference-count":249,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.prp.2026.156425","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T16:03:29Z","timestamp":1772294609000},"page":"156425","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Interactions and communications in hepatocellular carcinoma: Potential targets for chemo\/radiosensitization"],"prefix":"10.1016","volume":"282","author":[{"given":"Xiu","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meihua","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.prp.2026.156425_bib1","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/iub.597","article-title":"Association of nonalcoholic fatty liver disease with a single nucleotide polymorphism on the gene encoding leptin receptor","volume":"64","author":"Swellam","year":"2012","journal-title":"IUBMB life"},{"issue":"15","key":"10.1016\/j.prp.2026.156425_bib2","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3390\/cells13151245","article-title":"A comprehensive insight and in silico analysis of CircRNAs in hepatocellular carcinoma: a step toward ncRNA-based precision medicine","volume":"13","author":"Youness","year":"2024","journal-title":"Cells"},{"issue":"12","key":"10.1016\/j.prp.2026.156425_bib3","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/s41571-023-00825-3","article-title":"Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy","volume":"20","author":"Singal","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.prp.2026.156425_bib4","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/jvh.13452","article-title":"Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: a systematic review and meta-analysis","volume":"28","author":"Campbell","year":"2021","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.prp.2026.156425_bib5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/hep.31288","article-title":"Epidemiology of hepatocellular carcinoma","volume":"73","author":"McGlynn","year":"2021","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.prp.2026.156425_bib6","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3390\/jox15040096","article-title":"Cooperation Between Aflatoxin-Induced p53 Aberrations and Hepatitis B Virus in Hepatocellular Carcinoma","volume":"15","author":"Moreno-Le\u00f3n","year":"2025","journal-title":"J. Xenobiotics"},{"issue":"12","key":"10.1016\/j.prp.2026.156425_bib7","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1016\/j.cgh.2024.06.026","article-title":"Global prevalence, clinical characteristics, surveillance, treatment allocation, and outcomes of alcohol-associated hepatocellular carcinoma","volume":"22","author":"Zeng","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.prp.2026.156425_bib8","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.221429","article-title":"Imaging to predict prognosis in hepatocellular carcinoma: current and future perspectives","volume":"307","author":"Ronot","year":"2023","journal-title":"Radiology"},{"issue":"11","key":"10.1016\/j.prp.2026.156425_bib9","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.3390\/cancers13112621","article-title":"The endless sources of hepatocellular carcinoma heterogeneity","volume":"13","author":"Barcena-Varela","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2026.156425_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106427","article-title":"New trends in synthetic drugs and natural products targeting 20S proteasomes in cancers","volume":"133","author":"Atta","year":"2023","journal-title":"Bioorg. Chem."},{"issue":"7","key":"10.1016\/j.prp.2026.156425_bib11","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1245\/s10434-022-11454-y","article-title":"Clinical features of recurrence after hepatic resection for early-stage hepatocellular carcinoma and long-term survival outcomes of patients with recurrence: a multi-institutional analysis","volume":"29","author":"Yao","year":"2022","journal-title":"Ann. Surg. Oncol."},{"issue":"4","key":"10.1016\/j.prp.2026.156425_bib12","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.31557\/APJCP.2021.22.4.1255","article-title":"Quality of life after transcatheter arterial chemoembolization combined with radiofrequency ablation in patients with unresectable hepatocellular carcinoma compared with transcatheter arterial chemoembolization alone","volume":"22","author":"Hassanin","year":"2021","journal-title":"Asian Pacific Journal Cancer Prevention APJCP"},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib13","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.prp.2026.156425_bib14","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3350\/cmh.2022.0391","article-title":"Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity","volume":"29","author":"Iwamoto","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"issue":"2","key":"10.1016\/j.prp.2026.156425_bib15","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.3390\/curroncol30020190","article-title":"Stereotactic body radiotherapy for hepatocellular carcinoma: a brief overview","volume":"30","author":"Matsuo","year":"2023","journal-title":"Curr. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2174\/0113816128277350231219062154","article-title":"Differential signaling pathways in medulloblastoma: nano-biomedicine targeting non-coding epigenetics to improve current and future therapeutics","volume":"30","author":"Sokolov","year":"2024","journal-title":"Curr. Pharm. Des."},{"issue":"5","key":"10.1016\/j.prp.2026.156425_bib17","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.3390\/ijms26051839","article-title":"Radioresistance in Hepatocellular Carcinoma: Biological Bases and Therapeutic Implications","volume":"26","author":"Wu","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib18","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12935-018-0538-7","article-title":"Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight","volume":"18","author":"Lohitesh","year":"2018","journal-title":"Cancer Cell Int."},{"issue":"7","key":"10.1016\/j.prp.2026.156425_bib19","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.3390\/ijms25073904","article-title":"Hinokitiol inhibits breast cancer cells in vitro stemness-progression and self-renewal with apoptosis and autophagy modulation via the CD44\/Nanog\/SOX2\/Oct4 pathway","volume":"25","author":"Chiang","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.prp.2026.156425_bib20","first-page":"58","article-title":"The intergenic type LncRNA (LINC RNA) faces in cancer with in silico scope and a directed lens to LINC00511: a step toward ncRNA precision","volume":"9","author":"Eldash","year":"2023","journal-title":"Noncoding RNA"},{"key":"10.1016\/j.prp.2026.156425_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1008902","article-title":"The role of tumor microenvironment reprogramming in primary liver cancer chemotherapy resistance","volume":"12","author":"Zhao","year":"2022","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.prp.2026.156425_bib22","doi-asserted-by":"crossref","first-page":"165","DOI":"10.4254\/wjh.v7.i2.165","article-title":"Targeting the tumor stroma in hepatocellular carcinoma","volume":"7","author":"Heindryckx","year":"2015","journal-title":"World J. Hepatol."},{"issue":"3","key":"10.1016\/j.prp.2026.156425_bib23","doi-asserted-by":"crossref","first-page":"765","DOI":"10.21037\/tcr.2018.05.20","article-title":"Mechanisms of resistance to chemotherapy and radiotherapy in hepatocellular carcinoma","volume":"7","author":"Guo","year":"2018","journal-title":"Transl. Cancer Res."},{"issue":"4","key":"10.1016\/j.prp.2026.156425_bib24","doi-asserted-by":"crossref","first-page":"619","DOI":"10.3233\/CBM-160603","article-title":"Beclin-1 and hypoxia-inducible factor-1\u03b1 genes expression: potential biomarkers in acute leukemia patients","volume":"16","author":"Radwan","year":"2016","journal-title":"Cancer Biomark."},{"issue":"4","key":"10.1016\/j.prp.2026.156425_bib25","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1007\/s12029-021-00725-8","article-title":"Hepatocellular carcinoma tumor microenvironment and its implications in terms of anti-tumor immunity: future perspectives for new therapeutics","volume":"52","author":"Satilmis","year":"2021","journal-title":"J. Gastrointest. Cancer"},{"key":"10.1016\/j.prp.2026.156425_bib26","first-page":"1","article-title":"Redefining hepatocellular carcinoma treatment: nanotechnology meets tumor immune microenvironment","author":"Mi","year":"2025","journal-title":"J. Drug Target."},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib27","doi-asserted-by":"crossref","first-page":"98","DOI":"10.2174\/1566524023666221226143814","article-title":"Update on mesenchymal stem cells: a crucial player in cancer immunotherapy","volume":"24","author":"Taeb","year":"2024","journal-title":"Curr. Mol. Med."},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib28","doi-asserted-by":"crossref","first-page":"18","DOI":"10.2174\/1568009622666211224154952","article-title":"Role of tumor microenvironment in cancer stem cells resistance to radiotherapy","volume":"22","author":"Taeb","year":"2022","journal-title":"Curr. Cancer Drug Targets"},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib29","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41575-021-00508-3","article-title":"Cancer stem cells in hepatocellular carcinoma \u2014 from origin to clinical implications","volume":"19","author":"Lee","year":"2022","journal-title":"Nat. Rev. Gastroenterol. & Hepatol."},{"issue":"6","key":"10.1016\/j.prp.2026.156425_bib30","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1515\/jtim-2024-0020","article-title":"A Notch signaling pathway-related gene signature: Characterizing the immune microenvironment and predicting prognosis in hepatocellular carcinoma","volume":"12","author":"Shi","year":"2024","journal-title":"J. Transl. Int Med"},{"issue":"2","key":"10.1016\/j.prp.2026.156425_bib31","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.canlet.2011.10.012","article-title":"CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma","volume":"315","author":"Piao","year":"2012","journal-title":"Cancer Lett."},{"key":"10.1016\/j.prp.2026.156425_bib32","article-title":"The current status of tumor microenvironment and cancer stem cells in sorafenib resistance of hepatocellular carcinoma","volume":"13","author":"Chen","year":"2023","journal-title":"Front Oncol."},{"issue":"5","key":"10.1016\/j.prp.2026.156425_bib33","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/gastro\/goaa049","article-title":"Upregulation of PD-L1 expression promotes epithelial-to-mesenchymal transition in sorafenib-resistant hepatocellular carcinoma cells","volume":"8","author":"Xu","year":"2020","journal-title":"Gastroenterol. Rep. (Oxf. )"},{"key":"10.1016\/j.prp.2026.156425_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1483834","article-title":"The complex role of immune cells in antigen presentation and regulation of T-cell responses in hepatocellular carcinoma: progress, challenges, and future directions","volume":"15","author":"Ning","year":"2024","journal-title":"Front Immunol."},{"issue":"10","key":"10.1016\/j.prp.2026.156425_bib35","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/aps.2015.41","article-title":"Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy","volume":"36","author":"Sun","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib36","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1186\/s40425-019-0814-7","article-title":"PD1Hi CD8+ T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma","volume":"7","author":"Ma","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.prp.2026.156425_bib37","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/CJI.0000000000000166","article-title":"Transforming growth factor \u03b2 is a poor prognostic factor and inhibits the favorable prognostic value of CD8+ CTL in human hepatocellular carcinoma","volume":"40","author":"Huang","year":"2017","journal-title":"J. Immunother."},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib38","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s12967-020-02469-8","article-title":"Expression and clinical significance of LAG-3, FGL1, PD-L1 and CD8+ T cells in hepatocellular carcinoma using multiplex quantitative analysis","volume":"18","author":"Guo","year":"2020","journal-title":"J. Transl. Med."},{"issue":"6_ement","key":"10.1016\/j.prp.2026.156425_bib39","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1158\/1538-7445.AM2024-2660","article-title":"CXCL9\/10 is critical for immunotherapeutic efficacy by recruiting and activating T lymphocytes in tumor microenvironment","volume":"84","author":"Cheng","year":"2024","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.prp.2026.156425_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.110637","article-title":"Exploring the role of KIR3DL2 on NK cells in hepatocellular carcinoma and its potential prognostic implications","volume":"27","author":"Zhu","year":"2024","journal-title":"Iscience"},{"issue":"11","key":"10.1016\/j.prp.2026.156425_bib41","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.4254\/wjh.v7.i11.1572","article-title":"Th1\/Th2 cytokines and their genotypes as predictors of hepatitis B virus related hepatocellular carcinoma","volume":"7","author":"Saxena","year":"2015","journal-title":"World J. Hepatol."},{"issue":"22","key":"10.1016\/j.prp.2026.156425_bib42","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.3748\/wjg.v27.i22.2994","article-title":"Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment","volume":"27","author":"Granito","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.prp.2026.156425_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102310","article-title":"Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells","volume":"104","author":"Alissafi","year":"2019","journal-title":"J. Autoimmun."},{"issue":"5","key":"10.1016\/j.prp.2026.156425_bib44","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/hep.31792","article-title":"Cancer-associated fibroblast-mediated cellular crosstalk supports hepatocellular carcinoma progression","volume":"73","author":"Song","year":"2021","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib45","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1186\/s13046-018-0965-2","article-title":"Hepatocellular carcinoma-derived exosomal miRNA-21 contributes to tumor progression by converting hepatocyte stellate cells to cancer-associated fibroblasts","volume":"37","author":"Zhou","year":"2018","journal-title":"J. Exp. & Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib46","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1186\/s12967-022-03778-w","article-title":"Heterogeneous matrix stiffness regulates the cancer stem-like cell phenotype in hepatocellular carcinoma","volume":"20","author":"Wei","year":"2022","journal-title":"J. Transl. Med"},{"issue":"22","key":"10.1016\/j.prp.2026.156425_bib47","doi-asserted-by":"crossref","first-page":"32221","DOI":"10.18632\/oncotarget.8515","article-title":"Matrix stiffness-mediated effects on stemness characteristics occurring in HCC cells","volume":"7","author":"You","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib48","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/s41419-025-07842-3","article-title":"Matrix stiffness regulates glucose-6-phosphate dehydrogenase expression to mediate sorafenib resistance in hepatocellular carcinoma through the ITGB1-PI3K\/AKT pathway","volume":"16","author":"Ren","year":"2025","journal-title":"Cell Death Dis."},{"issue":"9","key":"10.1016\/j.prp.2026.156425_bib49","article-title":"The extracellular matrix in hepatocellular carcinoma: Mechanisms and therapeutic vulnerability","volume":"4","author":"Roy","year":"2023","journal-title":"Cell Rep. Med"},{"issue":"12","key":"10.1016\/j.prp.2026.156425_bib50","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/s41419-021-04418-9","article-title":"Matrix stiffness modulates hepatic stellate cell activation into tumor-promoting myofibroblasts via E2F3-dependent signaling and regulates malignant progression","volume":"12","author":"Liu","year":"2021","journal-title":"Cell Death Dis."},{"issue":"Pt A","key":"10.1016\/j.prp.2026.156425_bib51","article-title":"Fibronectin 1 derived from tumor-associated macrophages and fibroblasts promotes metastasis through the JUN pathway in hepatocellular carcinoma","volume":"113","author":"Zhang","year":"2022","journal-title":"Int Immunopharmacol."},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib52","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.canlet.2016.05.022","article-title":"Cancer-associated fibroblasts promote hepatocellular carcinoma metastasis through chemokine-activated hedgehog and TGF-\u03b2 pathways","volume":"379","author":"Liu","year":"2016","journal-title":"Cancer Lett."},{"issue":"14","key":"10.1016\/j.prp.2026.156425_bib53","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.7150\/ijbs.45446","article-title":"Cancer-associated Fibroblasts induce epithelial-mesenchymal transition via the Transglutaminase 2-dependent IL-6\/IL6R\/STAT3 axis in Hepatocellular Carcinoma","volume":"16","author":"Jia","year":"2020","journal-title":"Int. J. Biol. Sci."},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41421-024-00747-z","article-title":"Stromal architecture and fibroblast subpopulations with opposing effects on outcomes in hepatocellular carcinoma","volume":"11","author":"Cheng","year":"2025","journal-title":"Cell Discov."},{"issue":"2","key":"10.1016\/j.prp.2026.156425_bib55","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1096\/fj.201700721R","article-title":"FAK controls the mechanical activation of YAP, a transcriptional regulator required for durotaxis","volume":"32","author":"Lachowski","year":"2018","journal-title":"Faseb J."},{"issue":"10","key":"10.1016\/j.prp.2026.156425_bib56","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1016\/j.celrep.2017.02.041","article-title":"Agrin as a Mechanotransduction Signal Regulating YAP through the Hippo Pathway","volume":"18","author":"Chakraborty","year":"2017","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib57","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1186\/s12885-023-11613-8","article-title":"Cancer-associated fibroblasts induce sorafenib resistance of hepatocellular carcinoma cells through CXCL12\/FOLR1","volume":"23","author":"Zhao","year":"2023","journal-title":"BMc Cancer"},{"key":"10.1016\/j.prp.2026.156425_bib58","article-title":"Cancer-associated fibroblasts in hepatocellular carcinoma: Origins, heterogeneity, and therapeutic implications","volume":"16","author":"Shi","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2026.156425_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2025.114424","article-title":"Cancer-associated fibroblast-derived exosomes in cancer progression: A focus on hepatocellular carcinoma","author":"Hsu","year":"2025","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.prp.2026.156425_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109372","article-title":"Chemokine CCL5 immune subtypes of human liver cancer with prognostic significance","volume":"113","author":"Xia","year":"2022","journal-title":"Int. Immunopharmacol."},{"issue":"5","key":"10.1016\/j.prp.2026.156425_bib61","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/s41419-022-04935-1","article-title":"Cancer associated fibroblast\u2013derived CCL5 promotes hepatocellular carcinoma metastasis through activating HIF1\u03b1\/ZEB1 axis","volume":"13","author":"Xu","year":"2022","journal-title":"Cell death & Dis."},{"issue":"17","key":"10.1016\/j.prp.2026.156425_bib62","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1158\/0008-5472.CAN-17-3844","article-title":"CTGF mediates tumor\u2013stroma interactions between hepatoma cells and hepatic stellate cells to accelerate HCC progression","volume":"78","author":"Makino","year":"2018","journal-title":"Cancer Res."},{"issue":"21","key":"10.1016\/j.prp.2026.156425_bib63","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1097\/CM9.0000000000001726","article-title":"Crosstalk between hepatic stellate cells and tumor cells in the development of hepatocellular carcinoma","volume":"134","author":"Ma","year":"2021","journal-title":"Chin. Med. J."},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib64","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s13046-018-0908-y","article-title":"HSCs-derived COMP drives hepatocellular carcinoma progression by activating MEK\/ERK and PI3K\/AKT signaling pathways","volume":"37","author":"Li","year":"2018","journal-title":"J. Exp. & Clin. Cancer Res."},{"key":"10.1016\/j.prp.2026.156425_bib65","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.627927","article-title":"Activated hepatic stellate cells induce infiltration and formation of CD163+ macrophages via CCL2\/CCR2 pathway","volume":"8","author":"Xi","year":"2021","journal-title":"Front. Med."},{"issue":"12","key":"10.1016\/j.prp.2026.156425_bib66","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1007\/s00262-019-02414-9","article-title":"Activated hepatic stellate cells regulate MDSC migration through the SDF-1\/CXCR4 axis in an orthotopic mouse model of hepatocellular carcinoma","volume":"68","author":"Xu","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib67","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3390\/cells10010123","article-title":"Hedgehog signaling, a critical pathway governing the development and progression of hepatocellular carcinoma","volume":"10","author":"Ding","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.prp.2026.156425_bib68","series-title":"Seminars in liver disease","article-title":"TGF-\u03b2 as multifaceted orchestrator in HCC progression: signaling, EMT, immune microenvironment, and novel therapeutic perspectives","author":"Dituri","year":"2019"},{"issue":"10","key":"10.1016\/j.prp.2026.156425_bib69","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.3390\/ijms21103599","article-title":"Understanding the Differentiation, Expansion, Recruitment and Suppressive Activities of Myeloid-Derived Suppressor Cells in Cancers","volume":"21","author":"Lim","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.prp.2026.156425_bib70","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001223","article-title":"Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation","volume":"8","author":"Cassetta","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.prp.2026.156425_bib71","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00262-019-02302-2","article-title":"Deciphering myeloid-derived suppressor cells: isolation and markers in humans, mice and non-human primates","volume":"68","author":"Cassetta","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"issue":"3","key":"10.1016\/j.prp.2026.156425_bib72","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","article-title":"The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment","volume":"37","author":"Kumar","year":"2016","journal-title":"Trends Immunol."},{"issue":"12","key":"10.1016\/j.prp.2026.156425_bib73","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0225327","article-title":"The prognostic value of myeloid derived suppressor cell level in hepatocellular carcinoma: A systematic review and meta-analysis","volume":"14","author":"Zhang","year":"2019","journal-title":"PLOS ONE"},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib74","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12964-025-02170-7","article-title":"The immunosuppressive role of MDSCs in HCC: mechanisms and therapeutic opportunities","volume":"23","author":"Liu","year":"2025","journal-title":"Cell Commun. Signal."},{"issue":"6","key":"10.1016\/j.prp.2026.156425_bib75","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.7150\/thno.105276","article-title":"Metabolic regulation of myeloid-derived suppressor cells in tumor immune microenvironment: targets and therapeutic strategies","volume":"15","author":"Wang","year":"2025","journal-title":"Theranostics"},{"key":"10.1016\/j.prp.2026.156425_bib76","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.975261","article-title":"Role of myeloid-derived suppressor cells in the formation of pre-metastatic niche","volume":"12","author":"Ya","year":"2022","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.prp.2026.156425_bib77","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.323","article-title":"The recent progress of myeloid-derived suppressor cell and its targeted therapies in cancers","volume":"4","author":"Ren","year":"2023","journal-title":"MedComm"},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib78","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s40425-019-0697-7","article-title":"Natural killer T cell activation increases iNOS+CD206- M1 macrophage and controls the growth of solid tumor","volume":"7","author":"Paul","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"1-2","key":"10.1016\/j.prp.2026.156425_bib79","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s11010-016-2687-0","article-title":"Interleukin-12 inhibits the hepatocellular carcinoma growth by inducing macrophage polarization to the M1-like phenotype through downregulation of Stat-3","volume":"415","author":"Wang","year":"2016","journal-title":"Mol. Cell Biochem"},{"issue":"8","key":"10.1016\/j.prp.2026.156425_bib80","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/s41419-018-0818-0","article-title":"Crosstalk between hepatic tumor cells and macrophages via Wnt\/\u03b2-catenin signaling promotes M2-like macrophage polarization and reinforces tumor malignant behaviors","volume":"9","author":"Yang","year":"2018","journal-title":"Cell Death & Dis."},{"issue":"10","key":"10.1016\/j.prp.2026.156425_bib81","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1221557","article-title":"Hepatocellular carcinoma is accelerated by NASH involving M2 macrophage polarization mediated by hif-1\u03b1induced IL-10","volume":"5","author":"Ambade","year":"2016","journal-title":"OncoImmunology"},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib82","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-70137-4","article-title":"Hepatocellular carcinoma-derived high mobility group box 1 triggers M2 macrophage polarization via a TLR2\/NOX2\/autophagy axis","volume":"10","author":"Shiau","year":"2020","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.prp.2026.156425_bib83","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jhep.2014.10.029","article-title":"Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma","volume":"62","author":"Yeung","year":"2015","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib84","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12957-018-1312-y","article-title":"M2-polarized tumor-associated macrophages facilitated migration and epithelial-mesenchymal transition of HCC cells via the TLR4\/STAT3 signaling pathway","author":"Yao","year":"2018","journal-title":"World J. Surg. Oncol."},{"issue":"5","key":"10.1016\/j.prp.2026.156425_bib85","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.7150\/jca.35444","article-title":"M2 Macrophages Promote HCC Cells Invasion and Migration via miR-149-5p\/MMP9 Signaling","volume":"11","author":"Liu","year":"2020","journal-title":"J. Cancer"},{"issue":"7","key":"10.1016\/j.prp.2026.156425_bib86","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1038\/s43018-024-00775-4","article-title":"Tumor-associated macrophages restrict CD8+ T cell function through collagen deposition and metabolic reprogramming of the breast cancer microenvironment","volume":"5","author":"Tharp","year":"2024","journal-title":"Nat. Cancer"},{"issue":"6","key":"10.1016\/j.prp.2026.156425_bib87","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00262-024-03675-9","article-title":"Extracellular matrix stiffness and tumor-associated macrophage polarization: new fields affecting immune exclusion","volume":"73","author":"Yu","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"issue":"12","key":"10.1016\/j.prp.2026.156425_bib88","doi-asserted-by":"crossref","first-page":"6560","DOI":"10.3390\/ijms22126560","article-title":"The impact of the tumor microenvironment on macrophage polarization in cancer metastatic progression","volume":"22","author":"Wang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.prp.2026.156425_bib89","first-page":"5871","article-title":"Hypoxia modifies the polarization of macrophages and their inflammatory microenvironment, and inhibits malignant behavior in cancer cells","volume":"18","author":"Ke","year":"2019","journal-title":"Oncol. Lett."},{"issue":"8","key":"10.1016\/j.prp.2026.156425_bib90","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1158\/0008-5472.CAN-12-3542","article-title":"Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment","volume":"73","author":"Dijkgraaf","year":"2013","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.prp.2026.156425_bib91","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.2174\/1568026623666230201145909","article-title":"Tumor-associated macrophages (TAMs) in cancer resistance; modulation by natural products","volume":"23","author":"Lafta","year":"2023","journal-title":"Curr. Top. Med. Chem."},{"issue":"8","key":"10.1016\/j.prp.2026.156425_bib92","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1158\/1535-7163.MCT-16-0866","article-title":"Colony-Stimulating Factor 1 Receptor Blockade Inhibits Tumor Growth by Altering the Polarization of Tumor-Associated Macrophages in Hepatocellular Carcinoma","volume":"16","author":"Ao","year":"2017","journal-title":"Mol. Cancer Ther."},{"issue":"20","key":"10.1016\/j.prp.2026.156425_bib93","doi-asserted-by":"crossref","first-page":"8067","DOI":"10.1158\/0008-5472.CAN-09-0901","article-title":"Kupffer Cell Suppression of CD8+ T Cells in Human Hepatocellular Carcinoma Is Mediated by B7-H1\/Programmed Death-1 Interactions","volume":"69","author":"Wu","year":"2009","journal-title":"Cancer Res."},{"issue":"16","key":"10.1016\/j.prp.2026.156425_bib94","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1158\/0008-5472.CAN-12-0938","article-title":"The Proinflammatory Myeloid Cell Receptor TREM-1 Controls Kupffer Cell Activation and Development of Hepatocellular Carcinoma","volume":"72","author":"Wu","year":"2012","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.prp.2026.156425_bib95","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.jcmgh.2023.02.011","article-title":"Shp2 Deficiency in Kupffer Cells and Hepatocytes Aggravates Hepatocarcinogenesis by Recruiting Non-Kupffer Macrophages","volume":"15","author":"Du","year":"2023","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib96","doi-asserted-by":"crossref","first-page":"285","DOI":"10.7150\/ijbs.97109","article-title":"Kupffer Cell-derived IL6 Promotes Hepatocellular Carcinoma Metastasis Via the JAK1-ACAP4 Pathway","volume":"21","author":"Li","year":"2025","journal-title":"Int J. Biol. Sci."},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib97","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.yexcr.2018.09.001","article-title":"Tumor-endothelial cell interaction in an experimental model of human hepatocellular carcinoma","volume":"372","author":"Jamshidi-Parsian","year":"2018","journal-title":"Exp. Cell Res."},{"issue":"15","key":"10.1016\/j.prp.2026.156425_bib98","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.1158\/1078-0432.CCR-08-2780","article-title":"Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells","volume":"15","author":"Xiong","year":"2009","journal-title":"Clin. Cancer Res"},{"issue":"8","key":"10.1016\/j.prp.2026.156425_bib99","article-title":"Vessels that encapsulate tumour clusters vascular pattern in hepatocellular carcinoma","volume":"5","author":"Liu","year":"2023","journal-title":"JHEP Rep."},{"issue":"3","key":"10.1016\/j.prp.2026.156425_bib100","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1124\/mol.116.107706","article-title":"Advances in Hypoxia-Mediated Mechanisms in Hepatocellular Carcinoma","volume":"92","author":"Xiong","year":"2017","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.prp.2026.156425_bib101","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.3389\/fonc.2022.1063423","article-title":"Research progress of abnormal lactate metabolism and lactate modification in immunotherapy of hepatocellular carcinoma [Review]","volume":"12","author":"Xu","year":"2023","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.prp.2026.156425_bib102","doi-asserted-by":"crossref","first-page":"876","DOI":"10.3390\/cancers16050876","article-title":"Impact of Hypoxia on Radiation-Based Therapies for Liver Cancer","volume":"16","author":"Villalobos","year":"2024","journal-title":"Cancers"},{"issue":"null","key":"10.1016\/j.prp.2026.156425_bib103","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.2147\/CMAR.S537930","article-title":"Angiogenesis and Immunosuppressive Niche in Hepatocellular Carcinoma: Reshaping Vascular - Immune Axis to Potentiate antiPD - 1\/PD - L1 Therapy","volume":"17","author":"Li","year":"2025","journal-title":"Cancer Manag. Res."},{"issue":"null","key":"10.1016\/j.prp.2026.156425_bib104","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2147\/JHC.S61146","article-title":"Hepatocellular carcinoma: a review","volume":"3","author":"Balogh","year":"2016","journal-title":"J. Hepatocell. Carcinoma"},{"issue":"4","key":"10.1016\/j.prp.2026.156425_bib105","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrgastro.2016.193","article-title":"Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches","volume":"14","author":"Sapisochin","year":"2017","journal-title":"Nat. Rev. Gastroenterol. & Hepatol."},{"issue":"null","key":"10.1016\/j.prp.2026.156425_bib106","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2147\/JHC.S300182","article-title":"Hepatocellular Carcinoma: An Overview of the Changing Landscape of Treatment Options","volume":"8","author":"Koulouris","year":"2021","journal-title":"J. Hepatocell. Carcinoma"},{"issue":"2","key":"10.1016\/j.prp.2026.156425_bib107","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ccell.2024.01.007","article-title":"Precision treatment in advanced hepatocellular carcinoma","volume":"42","author":"Yang","year":"2024","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.prp.2026.156425_bib108","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1159\/000499765","article-title":"Systemic Treatment Options in Hepatocellular Carcinoma","volume":"8","author":"Rimassa","year":"2019","journal-title":"Liver Cancer"},{"issue":"10126","key":"10.1016\/j.prp.2026.156425_bib109","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.prp.2026.156425_bib110","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.4251\/wjgo.v14.i8.1510","article-title":"Second-line therapy for advanced hepatocellular carcinoma with regorafenib or cabozantinib: Multicenter French clinical experience in real-life after matching","volume":"14","author":"Adhoute","year":"2022","journal-title":"World J. Gastrointest. Oncol."},{"issue":"7","key":"10.1016\/j.prp.2026.156425_bib111","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1158\/1078-0432.CCR-20-3407","article-title":"FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma","volume":"27","author":"Casak","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib112","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1186\/s12885-023-11298-z","article-title":"Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma","volume":"23","author":"Chen","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.prp.2026.156425_bib113","doi-asserted-by":"crossref","first-page":"S688","DOI":"10.1016\/j.annonc.2020.08.1097","article-title":"981O Hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin, fluorouracil, and leucovorin (FOLFOX) versus transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (HCC): A randomised phase III trial","volume":"31","author":"Shi","year":"2020","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.prp.2026.156425_bib114","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1002\/jcp.27078","article-title":"Cirrhotic stiffness affects the migration of hepatocellular carcinoma cells and induces sorafenib resistance through YAP","volume":"234","author":"Gao","year":"2019","journal-title":"J. Cell. Physiol."},{"issue":"3","key":"10.1016\/j.prp.2026.156425_bib115","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/14740338.2021.1969360","article-title":"Fatigue and its management in cancer patients undergoing VEGFR-TKI therapy","volume":"21","author":"Takahashi","year":"2022","journal-title":"Expert Opin. Drug Saf."},{"issue":"12","key":"10.1016\/j.prp.2026.156425_bib116","article-title":"Immunotherapy for Cancer: Common Gastrointestinal, Liver, and Pancreatic Side Effects and Their Management","volume":"117","author":"Sedano","year":"2022","journal-title":"Off. J. Am. Coll. Gastroenterol. | ACG"},{"issue":"2","key":"10.1016\/j.prp.2026.156425_bib117","doi-asserted-by":"crossref","first-page":"578","DOI":"10.4103\/jcrt.jcrt_1549_23","article-title":"Hepatic artery infusion chemotherapy with systemic capecitabine and camrelizumab for treating unresectable hilar cholangiocarcinoma: An initial investigation of efficacy and safety","volume":"20","author":"Li","year":"2024","journal-title":"J. Cancer Res Ther."},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib118","doi-asserted-by":"crossref","DOI":"10.1097\/JS9.0000000000002089","article-title":"Radiation-emitting metallic stent for unresectable Bismuth type III or IV perihilar cholangiocarcinoma: a multicenter randomized trial","volume":"111","author":"Chen","year":"2025","journal-title":"Int. J. Surg."},{"issue":"18","key":"10.1016\/j.prp.2026.156425_bib119","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.3390\/cancers14184383","article-title":"The Current Role of Stereotactic Body Radiation Therapy (SBRT) in Hepatocellular Carcinoma (HCC)","volume":"14","author":"Kimura","year":"2022","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.prp.2026.156425_bib120","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00066-021-01854-6","article-title":"Indications of IMRT, PRT and CIRT for HCC from comparisons of dosimetry and normal tissue complication possibility","volume":"198","author":"Sun","year":"2022","journal-title":"Strahlenther. und Onkol."},{"issue":"20","key":"10.1016\/j.prp.2026.156425_bib121","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.3390\/cancers15204914","article-title":"The Current Evidence of Intensity-Modulated Radiotherapy for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis","volume":"15","author":"Jang","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib122","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s13014-020-01605-4","article-title":"Proton versus photon radiotherapy for primary hepatocellular carcinoma: a propensity-matched analysis","volume":"15","author":"Cheng","year":"2020","journal-title":"Radiat. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib123","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4254\/wjh.v7.i1.101","article-title":"Role of radiotherapy in the management of hepatocellular carcinoma: A systematic review","volume":"7","author":"Kalogeridi","year":"2015","journal-title":"World J. Hepatol."},{"issue":"3","key":"10.1016\/j.prp.2026.156425_bib124","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1007\/s00261-024-04620-1","article-title":"Efficacy of radiotherapy combined with hepatic arterial infusion chemotherapy, TKI and ICI for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective cohort study","volume":"50","author":"Tan","year":"2025","journal-title":"Abdom. Radiol."},{"issue":"6","key":"10.1016\/j.prp.2026.156425_bib125","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ctrv.2015.03.011","article-title":"The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant","volume":"41","author":"Reynders","year":"2015","journal-title":"Cancer Treat. Rev."},{"issue":"21","key":"10.1016\/j.prp.2026.156425_bib126","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14215190","article-title":"A Systematic Review on the Impact of Hypofractionated and Stereotactic Radiotherapy on Immune Cell Subpopulations in Cancer Patients","volume":"14","author":"Takanen","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib127","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41698-020-0124-z","article-title":"Association of pro-inflammatory soluble cytokine receptors early during hepatocellular carcinoma stereotactic radiotherapy with liver toxicity","volume":"4","author":"Ng","year":"2020","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.prp.2026.156425_bib128","first-page":"20","article-title":"Shedding light on the role of LAG-3 in hepatocellular carcinoma: unraveling immunomodulatory pathways","volume":"10","author":"Konstantinos","year":"2024","journal-title":"Hepatoma Res."},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib129","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s12672-025-02914-4","article-title":"Stereotactic body radiation therapy (SBRT) increases anti-PD-1 antitumor activity by enhancing the tumor immune microenvironment in mice with metastatic hepatocellular carcinoma","volume":"16","author":"Xu","year":"2025","journal-title":"Discov. Oncol."},{"issue":"2","key":"10.1016\/j.prp.2026.156425_bib130","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ijrobp.2020.12.031","article-title":"Enlightening the Immune Mechanism of the Abscopal Effect in a Murine HCC Model and Overcoming the Late Resistance With Anti-PD-L1","volume":"110","author":"Park","year":"2021","journal-title":"Int. J. Radiat. Oncol. *Biol. *Phys."},{"issue":"7","key":"10.1016\/j.prp.2026.156425_bib131","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/hepr.12789","article-title":"Programmed cell death-1 blockade enhances response to stereotactic radiation in an orthotopic murine model of hepatocellular carcinoma","volume":"47","author":"Friedman","year":"2017","journal-title":"Hepatol. Res."},{"issue":"5","key":"10.1016\/j.prp.2026.156425_bib132","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.ijrobp.2021.12.162","article-title":"Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation","volume":"112","author":"Du","year":"2022","journal-title":"Int. J. Radiat. Oncol. *Biol. *Phys."},{"issue":"5","key":"10.1016\/j.prp.2026.156425_bib133","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/jgh.15319","article-title":"Combination therapy with anti-T-cell immunoglobulin and mucin-domain containing molecule 3 and radiation improves antitumor efficacy in murine hepatocellular carcinoma","volume":"36","author":"Kim","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib134","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s40364-025-00820-z","article-title":"Combination immunotherapy targeting LAG-3, PD-1 and STING suppresses hepatocellular carcinoma as monitored by LAG-3 targeted PET imaging","volume":"13","author":"Quan","year":"2025","journal-title":"Biomark. Res."},{"key":"10.1016\/j.prp.2026.156425_bib135","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.686621","article-title":"Safety of PD-1\/PD-L1 Inhibitors Combined With Palliative Radiotherapy and Anti-Angiogenic Therapy in Advanced Hepatocellular Carcinoma","volume":"11","author":"Zhong","year":"2021","journal-title":"Front Oncol."},{"issue":"5","key":"10.1016\/j.prp.2026.156425_bib136","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.ijrobp.2024.03.035","article-title":"Stereotactic Body Radiotherapy Combined With Lenvatinib With or Without PD-1 Inhibitors as Initial Treatment for Unresectable Hepatocellular Carcinoma","volume":"120","author":"Wang","year":"2024","journal-title":"Int. J. Radiat. Oncol. *Biol. *Phys."},{"key":"10.1016\/j.prp.2026.156425_bib137","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2147\/JHC.S480691","article-title":"Impact of Timing the Combination of Radiotherapy and PD-1 Inhibitors on Outcomes in Patients with Hepatocellular Carcinoma","author":"Zhong","year":"2025","journal-title":"J. Hepatocell. Carcinoma"},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib138","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13014-023-02309-1","article-title":"Radiotherapy plus anti-PD1 versus radiotherapy for hepatic toxicity in patients with hepatocellular carcinoma","volume":"18","author":"Zhang","year":"2023","journal-title":"Radiat. Oncol."},{"key":"10.1016\/j.prp.2026.156425_bib139","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.3389\/fonc.2022.839605","article-title":"Effects of Stereotactic Body Radiation Therapy Plus PD-1 Inhibitors for Patients With Transarterial Chemoembolization Refractory [Original Research]","volume":"12","author":"Xiang","year":"2022","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.prp.2026.156425_bib140","first-page":"1606","article-title":"Proton beam radiotherapy combined with anti-PD1\/PDL1 immune checkpoint inhibitors for advanced hepatocellular carcinoma","volume":"12","author":"Su","year":"2022","journal-title":"Am. J. Cancer Res"},{"issue":"3","key":"10.1016\/j.prp.2026.156425_bib141","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1159\/000533425","article-title":"Survival Outcome Analysis of Stereotactic Body Radiotherapy and Immunotherapy (SBRT-IO) versus SBRT-Alone in Unresectable Hepatocellular Carcinoma","volume":"13","author":"Chiang","year":"2024","journal-title":"Liver Cancer"},{"issue":"null","key":"10.1016\/j.prp.2026.156425_bib142","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.2147\/ITT.S538796","article-title":"Clinical Outcomes and Hepatic Toxicity of Combined Intensity Modulated Radiotherapy and PD-1 Inhibitors in Child-Pugh Class B Advanced Hepatocellular Carcinoma","volume":"14","author":"Chen","year":"2025","journal-title":"ImmunoTargets Ther."},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib143","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s40425-019-0692-z","article-title":"Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade","volume":"7","author":"Liu","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib144","first-page":"38","article-title":"Treatments of transarterial chemoembolization (TACE), stereotactic body radiotherapy (SBRT) and immunotherapy reshape the systemic tumor immune environment (STIE) in patients with unresectable hepatocellular carcinoma","volume":"5","author":"Zhao","year":"2025","journal-title":"J. Natl. Cancer Cent."},{"issue":"11","key":"10.1016\/j.prp.2026.156425_bib145","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1097\/CM9.0000000000003124","article-title":"Radiotherapy enhances efficacy of PD-1 inhibitors in advanced hepatocellular carcinoma: A propensity-matched real-world study","volume":"137","author":"Hsu","year":"2024","journal-title":"Chin. Med J. (Engl. )"},{"issue":"20","key":"10.1016\/j.prp.2026.156425_bib146","doi-asserted-by":"crossref","first-page":"4088","DOI":"10.1158\/1078-0432.CCR-22-2592","article-title":"Efficacy and Safety of Stereotactic Body Radiotherapy Combined with Camrelizumab and Apatinib in Patients with Hepatocellular Carcinoma with Portal Vein Tumor Thrombus","volume":"29","author":"Hu","year":"2023","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.prp.2026.156425_bib147","doi-asserted-by":"crossref","first-page":"S598","DOI":"10.1016\/j.annonc.2023.09.2103","article-title":"957P Interim report of Notable-HCC: A phase Ib study of neoadjuvant PD-1 with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma (HCC)","volume":"34","author":"Li","year":"2023","journal-title":"Ann. Oncol."},{"issue":"15_","key":"10.1016\/j.prp.2026.156425_bib148","article-title":"Combining radiation therapy with anti-PD-1 for patients with advanced hepatocellular carcinoma: An open-label, single-center, single-arm clinical study","volume":"39","author":"Li","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156425_bib149","doi-asserted-by":"crossref","unstructured":"Xiang Y.-J., Wang K., Zheng Y.-T., et al. Efficacy of Stereotactic Body Radiation Therapy in Patients With Pd-1 Inhibitor\u2013transarterial Chemoembolization Refractory Intermediate-stage Hepatocellular Carcinoma: a Retrospective Controlled Study. 2021.","DOI":"10.21203\/rs.3.rs-958058\/v1"},{"key":"10.1016\/j.prp.2026.156425_bib150","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.3389\/fonc.2019.01157","article-title":"Combined Stereotactic Body Radiotherapy and Checkpoint Inhibition in Unresectable Hepatocellular Carcinoma: A Potential Synergistic Treatment Strategy [Case Report]","volume":"9","author":"Chiang","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2026.156425_bib151","article-title":"Pembrolizumab and stereotactic body radiotherapy combined in advanced hepatocellular carcinoma post sorafenib\u2013 A phase II trial (PEMRAD)","author":"O\u2019Kane","year":"2025","journal-title":"JHEP Rep."},{"key":"10.1016\/j.prp.2026.156425_bib152","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1591424","article-title":"SFRT combined with immunotherapy for a growing hepatocellular carcinoma after the failure of anti-angiogenesis and anti-PD1 treatment: a case report","volume":"15","author":"Hu","year":"2025","journal-title":"Front Oncol."},{"issue":"24","key":"10.1016\/j.prp.2026.156425_bib153","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.3748\/wjg.v29.i24.3871","article-title":"Stereotactic body radiotherapy combined with sintilimab in patients with recurrent or oligometastatic hepatocellular carcinoma: A phase II clinical trial","volume":"29","author":"Chen","year":"2023","journal-title":"World J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib154","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.radonc.2017.11.027","article-title":"Clinical significance of soluble programmed cell death ligand-1 (sPD-L1) in hepatocellular carcinoma patients treated with radiotherapy","volume":"129","author":"Kim","year":"2018","journal-title":"Radiother. Oncol."},{"issue":"5","key":"10.1016\/j.prp.2026.156425_bib155","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s12072-022-10396-7","article-title":"Combining stereotactic body radiotherapy with camrelizumab for unresectable hepatocellular carcinoma: a single-arm trial","volume":"16","author":"Li","year":"2022","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.prp.2026.156425_bib156","first-page":"2023","article-title":"Toripalimab in combination with Anlotinib for unresectable hepatocellular carcinoma after SBRT: A prospective, single-arm, single-center clinical study [Clinical Trial]","volume":"13","author":"Chen","year":"2023","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib157","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ijrobp.2022.09.052","article-title":"Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced\/Unresectable Hepatocellular Carcinoma","volume":"115","author":"Juloori","year":"2023","journal-title":"Int. J. Radiat. Oncol. *Biol. *Phys."},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib158","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1038\/s41467-024-47420-3","article-title":"Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial","volume":"15","author":"Li","year":"2024","journal-title":"Nat. Commun."},{"issue":"16_","key":"10.1016\/j.prp.2026.156425_bib159","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1200\/JCO.2022.40.16_suppl.4071","article-title":"A phase II study of stereotactic body radiotherapy (SBRT) combined with sintilimab in patients with recurrent or oligometastatic hepatocellular carcinoma (HCC)","volume":"40","author":"Chen","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"null","key":"10.1016\/j.prp.2026.156425_bib160","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.2147\/JHC.S432542","article-title":"Effectiveness and Safety of the PD-1 Inhibitor Lenvatinib Plus Radiotherapy in Patients with HCC with Main PVTT: Real-World Data from a Tertiary Centre","volume":"10","author":"Li","year":"2023","journal-title":"J. Hepatocell. Carcinoma"},{"issue":"20","key":"10.1016\/j.prp.2026.156425_bib161","doi-asserted-by":"crossref","first-page":"4088","DOI":"10.1158\/1078-0432.CCR-22-2592","article-title":"Efficacy and Safety of Stereotactic Body Radiotherapy Combined with Camrelizumab and Apatinib in Patients with Hepatocellular Carcinoma with Portal Vein Tumor Thrombus","volume":"29","author":"Hu","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2026.156425_bib162","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.3389\/fonc.2021.798832","article-title":"Combined Stereotactic Body Radiotherapy and Immunotherapy Versus Transarterial Chemoembolization in Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis [Original Research]","volume":"11","author":"Chiang","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2026.156425_bib163","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.3389\/fimmu.2022.972503","article-title":"PD-1 inhibitors plus anti-angiogenic therapy with or without intensity-modulated radiotherapy for advanced hepatocellular carcinoma: A propensity score matching study [Original Research]","volume":"13","author":"Su","year":"2022","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.prp.2026.156425_bib164","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jcmgh.2022.12.002","article-title":"Oxaliplatin-Resistant Hepatocellular Carcinoma Drives Immune Evasion Through PD-L1 Up-Regulation and PMN-Singular Recruitment","volume":"15","author":"Zhang","year":"2023","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.prp.2026.156425_bib165","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2021.101853","article-title":"Gemcitabine-facilitated modulation of the tumor microenvironment and PD-1\/PD-L1 blockade generate a synergistic antitumor effect in a murine hepatocellular carcinoma model","volume":"46","author":"Wang","year":"2022","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"issue":"6","key":"10.1016\/j.prp.2026.156425_bib166","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s13402-020-00552-2","article-title":"Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy","volume":"43","author":"Zhu","year":"2020","journal-title":"Cell. Oncol."},{"issue":"15_","key":"10.1016\/j.prp.2026.156425_bib167","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.1200\/JCO.2019.37.15_suppl.4074","article-title":"A phase II study of anti\u2013PD-1 antibody camrelizumab plus FOLFOX4 or GEMOX systemic chemotherapy as first-line therapy for advanced hepatocellular carcinoma or biliary tract cancer","volume":"37","author":"Qin","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156425_bib168","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.3389\/fonc.2021.618206","article-title":"Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitors Plus Lenvatinib Versus PD-1 Inhibitors Plus Lenvatinib for Advanced Hepatocellular Carcinoma [Original Research]","volume":"11","author":"Mei","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2026.156425_bib169","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.3389\/fonc.2022.1004652","article-title":"Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: A tertiary medical center experience [Original Research]","volume":"12","author":"Luo","year":"2022","journal-title":"Front. Oncol."},{"issue":"17","key":"10.1016\/j.prp.2026.156425_bib170","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.2217\/imt-2021-0192","article-title":"Real-world Study of Hepatic Artery Infusion Chemotherapy Combined With Anti-PD-1 Immunotherapy and Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma","volume":"13","author":"Liu","year":"2021","journal-title":"Immunotherapy"},{"key":"10.1016\/j.prp.2026.156425_bib171","first-page":"2023","article-title":"Hepatic arterial infusion chemotherapy combined with anti-PD-1\/PD-L1 immunotherapy and molecularly targeted agents for advanced hepatocellular carcinoma: a real world study [Original Research]","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib172","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s41392-023-01663-6","article-title":"Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.prp.2026.156425_bib173","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241231252","article-title":"Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy for hepatocellular carcinoma patients with portal vein tumor thrombus","volume":"16","author":"Li","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"4","key":"10.1016\/j.prp.2026.156425_bib174","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/jgh.16463","article-title":"Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for HCC refractory to TACE","volume":"39","author":"Diao","year":"2024","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"null","key":"10.1016\/j.prp.2026.156425_bib175","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.2147\/JHC.S457527","article-title":"PD-1 Inhibitors Combined with Tyrosine Kinase Inhibitors with or without Hepatic Artery Infusion Chemotherapy for the First-Line Treatment of HBV-Related Advanced Hepatocellular Carcinoma: A Retrospective Study","volume":"11","author":"Wang","year":"2024","journal-title":"J. Hepatocell. Carcinoma"},{"issue":"4_","key":"10.1016\/j.prp.2026.156425_bib176","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1200\/JCO.2023.41.4_suppl.578","article-title":"Tebotelimab, a PD-1\/LAG-3 bispecific antibody, in patients with advanced hepatocellular carcinoma who had failed prior targeted therapy and\/or immunotherapy: An open-label, single-arm, phase 1\/2 dose-escalation and expansion study","volume":"41","author":"Ren","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.prp.2026.156425_bib177","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1038\/s44321-024-00068-4","article-title":"TLR3 activation enhances abscopal effect of radiotherapy in HCC by promoting tumor ferroptosis","volume":"16","author":"Qiu","year":"2024","journal-title":"EMBO Mol. Med"},{"key":"10.1016\/j.prp.2026.156425_bib178","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jconrel.2024.12.064","article-title":"Iodine-131 radioembolization boosts the immune activation enhanced by icaritin\/resiquimod in hepatocellular carcinoma","volume":"378","author":"Li","year":"2025","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.prp.2026.156425_bib179","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00262-013-1504-9","article-title":"TLR4-dependant immune response, but not hepatitis B virus reactivation, is important in radiation-induced liver disease of liver cancer radiotherapy","volume":"63","author":"Wu","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.prp.2026.156425_bib180","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2024.111378","article-title":"Cancer-associated fibroblasts promote the progression and chemoresistance of HCC by inducing IGF-1","volume":"124","author":"Lv","year":"2024","journal-title":"Cell. Signal."},{"issue":"3","key":"10.1016\/j.prp.2026.156425_bib181","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1080\/21655979.2022.2032972","article-title":"Cancer-associated fibroblast exosomes promote chemoresistance to cisplatin in hepatocellular carcinoma through circZFR targeting signal transducers and activators of transcription (STAT3)\/ nuclear factor -kappa B (NF-\u03baB) pathway","volume":"13","author":"Zhou","year":"2022","journal-title":"Bioengineered"},{"issue":"14","key":"10.1016\/j.prp.2026.156425_bib182","doi-asserted-by":"crossref","first-page":"856","DOI":"10.21037\/atm-20-1038","article-title":"Cancer-associated fibroblasts enhance the chemoresistance of CD73(+) hepatocellular carcinoma cancer cells via HGF-Met-ERK1\/2 pathway","volume":"8","author":"Peng","year":"2020","journal-title":"Ann. Transl. Med"},{"issue":"5","key":"10.1016\/j.prp.2026.156425_bib183","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s13402-025-01088-z","article-title":"SOX4 mediates cancer-associated fibroblasts related radioresistance in hepatocellular carcinoma","volume":"48","author":"Jiang","year":"2025","journal-title":"Cell Oncol (Dordr)"},{"issue":"9","key":"10.1016\/j.prp.2026.156425_bib184","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0073312","article-title":"Hepatic Stellate Cells Secreted Hepatocyte Growth Factor Contributes to the Chemoresistance of Hepatocellular Carcinoma","volume":"8","author":"Yu","year":"2013","journal-title":"PLOS ONE"},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib185","article-title":"Activated hepatic stellate cells play pivotal roles in hepatocellular carcinoma cell chemoresistance and migration in multicellular tumor spheroids","volume":"6","author":"Song","year":"2016","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.prp.2026.156425_bib186","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.yexcr.2018.07.011","article-title":"Treatment-damaged hepatocellular carcinoma promotes activities of hepatic stellate cells and fibrosis through GDF15","volume":"370","author":"Dong","year":"2018","journal-title":"Exp. Cell Res."},{"issue":"2","key":"10.1016\/j.prp.2026.156425_bib187","doi-asserted-by":"crossref","first-page":"632","DOI":"10.3892\/ijo.2015.3024","article-title":"Protective effects of hepatic stellate cells against cisplatin-induced apoptosis in human hepatoma G2 cells","volume":"47","author":"Zhang","year":"2015","journal-title":"Int J. Oncol."},{"key":"10.1016\/j.prp.2026.156425_bib188","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121003","article-title":"Combined anti-hepatocellular carcinoma therapy inhibit drug-resistance and metastasis via targeting \u201csubstance P-hepatic stellate cells-hepatocellular carcinoma\u201d axis","volume":"276","author":"Li","year":"2021","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib189","first-page":"508","article-title":"Proteomic Profiling of Human Hepatic Stellate Cell Line LX2 Responses to Irradiation and TGF-\u03b21","volume":"18","author":"Yuan","year":"2019","journal-title":"J. Proteome Res."},{"issue":"4","key":"10.1016\/j.prp.2026.156425_bib190","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1667\/RADE-21-00129.1","article-title":"The Invasive Potential of Hepatoma Cells Induced by Radiotherapy is Related to the Activation of Hepatic Stellate Cells and Could be Inhibited by EGCG Through the TLR4 Signaling Pathway","volume":"197","author":"Shen","year":"2022","journal-title":"Radiat. Res."},{"issue":"7","key":"10.1016\/j.prp.2026.156425_bib191","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.3390\/biomedicines11072081","article-title":"Tumor-Associated Macrophages Affect the Tumor Microenvironment and Radioresistance via the Upregulation of CXCL6\/CXCR2 in Hepatocellular Carcinoma","volume":"11","author":"Lee","year":"2023","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.prp.2026.156425_bib192","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1198","article-title":"ALKBH5-mediated m6A demethylation of TIRAP mRNA promotes radiation-induced liver fibrosis and decreases radiosensitivity of hepatocellular carcinoma","volume":"13","author":"Chen","year":"2023","journal-title":"Clin. Transl. Med."},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib193","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jhep.2023.02.032","article-title":"TREM2+ macrophages suppress CD8+ T-cell infiltration after transarterial chemoembolisation in hepatocellular carcinoma","volume":"79","author":"Tan","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.prp.2026.156425_bib194","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112892","article-title":"Delivery of SiRNA-PD-L1 by attenuated Salmonella in combination with oxaliplatin in a hepatocellular carcinoma mouse model","volume":"141","author":"Chen","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"27","key":"10.1016\/j.prp.2026.156425_bib195","doi-asserted-by":"crossref","first-page":"44465","DOI":"10.18632\/oncotarget.17973","article-title":"M2 tumor-associated macrophages produce interleukin-17 to suppress oxaliplatin-induced apoptosis in hepatocellular carcinoma","volume":"8","author":"Guo","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib196","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12935-019-0771-8","article-title":"Tumor-associated macrophages modulate resistance to oxaliplatin via inducing autophagy in hepatocellular carcinoma","volume":"19","author":"Fu","year":"2019","journal-title":"Cancer Cell Int."},{"issue":"6","key":"10.1016\/j.prp.2026.156425_bib197","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1053\/j.gastro.2014.08.039","article-title":"Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells","volume":"147","author":"Wan","year":"2014","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.prp.2026.156425_bib198","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.canlet.2014.05.008","article-title":"Tumor-associated macrophages promote cancer stem cell-like properties via transforming growth factor-beta1-induced epithelial-mesenchymal transition in hepatocellular carcinoma","volume":"352","author":"Fan","year":"2014","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib199","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11010-020-03861-0","article-title":"Cisplatin promotes the expression level of PD-L1 in the microenvironment of hepatocellular carcinoma through YAP1","volume":"475","author":"Li","year":"2020","journal-title":"Mol. Cell. Biochem."},{"issue":"null","key":"10.1016\/j.prp.2026.156425_bib200","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2147\/JHC.S300165","article-title":"Blocking the CCL5\u2013CCR5 Axis Using Maraviroc Promotes M1 Polarization of Macrophages Cocultured with Irradiated Hepatoma Cells","volume":"8","author":"Zhuang","year":"2021","journal-title":"J. Hepatocell. Carcinoma"},{"key":"10.1016\/j.prp.2026.156425_bib201","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2021.130109","article-title":"Enhanced radiotherapy efficacy and induced anti-tumor immunity in HCC by improving hypoxia microenvironment using oxygen microcapsules","volume":"422","author":"Dai","year":"2021","journal-title":"Chem. Eng. J."},{"issue":"3","key":"10.1016\/j.prp.2026.156425_bib202","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00411-008-0170-3","article-title":"Irradiation leads to apoptosis of Kupffer cells by a Hsp27-dependant pathway followed by release of TNF-\u03b1","volume":"47","author":"Tello","year":"2008","journal-title":"Radiat. Environ. Biophys."},{"issue":"6","key":"10.1016\/j.prp.2026.156425_bib203","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00262-016-1837-2","article-title":"Myeloid-derived suppressor cells correlate with patient outcomes in hepatic arterial infusion chemotherapy for hepatocellular carcinoma","volume":"65","author":"Mizukoshi","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"issue":"8","key":"10.1016\/j.prp.2026.156425_bib204","doi-asserted-by":"crossref","first-page":"10427","DOI":"10.1007\/s13277-016-4916-2","article-title":"The clinical and prognostic significance of CD14+HLA-DR\u2212\/low myeloid-derived suppressor cells in hepatocellular carcinoma patients receiving radiotherapy","volume":"37","author":"Wang","year":"2016","journal-title":"Tumor Biol."},{"issue":"2","key":"10.1016\/j.prp.2026.156425_bib205","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.yexcr.2017.01.008","article-title":"Interactions between interleukin-6 and myeloid-derived suppressor cells drive the chemoresistant phenotype of hepatocellular cancer","volume":"351","author":"Xu","year":"2017","journal-title":"Exp. Cell Res."},{"issue":"2","key":"10.1016\/j.prp.2026.156425_bib206","article-title":"Chemotherapy-induced recruitment of myeloid-derived suppressor cells abrogates efficacy of immune checkpoint blockade","volume":"3","author":"Kwong","year":"2021","journal-title":"JHEP Rep."},{"issue":"6","key":"10.1016\/j.prp.2026.156425_bib207","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.447","article-title":"NLRP3\/IL-1\u03b2 induced myeloid-derived suppressor cells recruitment and PD-L1 upregulation promotes oxaliplatin resistance of hepatocellular carcinoma","volume":"4","author":"Liu","year":"2023","journal-title":"MedComm"},{"issue":"4","key":"10.1016\/j.prp.2026.156425_bib208","article-title":"DDR2\/STAT3 Positive Feedback Loop Mediates the Immunosuppressive Microenvironment by Upregulating PD-L1 and Recruiting MDSCs in Oxaliplatin-Resistant HCC","volume":"18","author":"Liu","year":"2024","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"issue":"9","key":"10.1016\/j.prp.2026.156425_bib209","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1477459","article-title":"Combination of radiation and interleukin 12 eradicates large orthotopic hepatocellular carcinoma through immunomodulation of tumor microenvironment","volume":"7","author":"Wu","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.prp.2026.156425_bib210","first-page":"2020","article-title":"Hypofractionated Irradiation Suppressed the Off-Target Mouse Hepatocarcinoma Growth by Inhibiting Myeloid-Derived Suppressor Cell-Mediated Immune Suppression [Original Research]","volume":"10","author":"Chen","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2026.156425_bib211","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.121715","article-title":"Periplocin inhibits hepatocellular carcinoma progression and reduces the recruitment of MDSCs through AKT\/NF-\u03baB pathway","volume":"324","author":"Lin","year":"2023","journal-title":"Life Sci."},{"issue":"3","key":"10.1016\/j.prp.2026.156425_bib212","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1007\/s12032-011-0006-x","article-title":"Intratumoral regulatory T cells alone or in combination with cytotoxic T cells predict prognosis of hepatocellular carcinoma after resection","volume":"29","author":"Chen","year":"2012","journal-title":"Med. Oncol."},{"issue":"2","key":"10.1016\/j.prp.2026.156425_bib213","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/MAJ.0b013e31826ceed0","article-title":"Akt Promotes Irradiation-Induced Regulatory T-Cell Survival in Hepatocellular Carcinoma","volume":"346","author":"Li","year":"2013","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.prp.2026.156425_bib214","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.biocel.2014.08.014","article-title":"Low-dose splenic radiation inhibits liver tumor development of rats through functional changes in CD4+CD25+Treg cells","volume":"55","author":"Wang","year":"2014","journal-title":"Int. J. Biochem. & Cell Biol."},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib215","doi-asserted-by":"crossref","first-page":"7709","DOI":"10.1038\/s41467-023-43462-1","article-title":"Low-dose radiotherapy combined with dual PD-L1 and VEGFA blockade elicits antitumor response in hepatocellular carcinoma mediated by activated intratumoral CD8+ exhausted-like T cells","volume":"14","author":"Li","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib216","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000340","article-title":"ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma","volume":"8","author":"Sheng","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.prp.2026.156425_bib217","doi-asserted-by":"crossref","DOI":"10.1177\/15347354211013085","article-title":"Cistanche tubulosa Phenylethanoid Glycosides Induce Apoptosis of Hepatocellular Carcinoma Cells by Mitochondria-Dependent and MAPK Pathways and Enhance Antitumor Effect through Combination with Cisplatin","volume":"20","author":"Yuan","year":"2021","journal-title":"Integr. Cancer Ther."},{"issue":"7","key":"10.1016\/j.prp.2026.156425_bib218","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/j.1349-7006.2012.02285.x","article-title":"SirT1 regulates radiosensitivity of hepatoma cells differently under normoxic and hypoxic conditions","volume":"103","author":"Xie","year":"2012","journal-title":"Cancer Sci."},{"issue":"15","key":"10.1016\/j.prp.2026.156425_bib219","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1158\/0008-5472.CAN-03-3311","article-title":"The Potential Role of Hypoxia Inducible Factor 1\u03b1 in Tumor Progression after Hypoxia and Chemotherapy in Hepatocellular Carcinoma","volume":"64","author":"Yang","year":"2004","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.prp.2026.156425_bib220","first-page":"1176","article-title":"Mechanism of Hypoxia-inducible Factor-1\u03b1 Inducing Drug Resistance to Oxaliplatin in Hepatic Carcinoma","volume":"41","author":"Fengmeng","year":"2014","journal-title":"Cancer Res. Prev. Treat."},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib221","doi-asserted-by":"crossref","first-page":"364","DOI":"10.18632\/aging.202137","article-title":"Enhancer-bound Nrf2 licenses HIF-1\u03b1 transcription under hypoxia to promote cisplatin resistance in hepatocellular carcinoma cells","volume":"13","author":"Jin","year":"2020","journal-title":"Aging (Albany NY)"},{"issue":"2","key":"10.1016\/j.prp.2026.156425_bib222","first-page":"461","article-title":"Activation of PI3 kinase\/Akt\/HIF-1\u03b1 pathway contributes to hypoxia-induced epithelial-mesenchymal transition and chemoresistance in hepatocellular carcinoma","volume":"40","author":"Jiao","year":"2012","journal-title":"Int J. Oncol."},{"issue":"8","key":"10.1016\/j.prp.2026.156425_bib223","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.4161\/auto.5.8.9996","article-title":"Hypoxia-induced autophagy contributes to the chemoresistance of hepatocellular carcinoma cells","volume":"5","author":"Song","year":"2009","journal-title":"Autophagy"},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib224","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12951-022-01316-w","article-title":"Robust radiosensitization of hemoglobin-curcumin nanoparticles suppresses hypoxic hepatocellular carcinoma","volume":"20","author":"Gao","year":"2022","journal-title":"J. Nanobiotechnology"},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib225","doi-asserted-by":"crossref","first-page":"508","DOI":"10.3892\/mmr.2021.12147","article-title":"LY\u2011294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K\/AKT\/HIF\u20111\u03b1 pathway","volume":"24","author":"Xu","year":"2021","journal-title":"Mol. Med Rep."},{"issue":"2","key":"10.1016\/j.prp.2026.156425_bib226","first-page":"2431","article-title":"Metformin attenuates hypoxia\u2011induced resistance to cisplatin in the HepG2 cell line","volume":"17","author":"Fujita","year":"2019","journal-title":"Oncol. Lett."},{"issue":"7","key":"10.1016\/j.prp.2026.156425_bib227","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0159530","article-title":"Assessment of Preoperative Liver Function in Patients with Hepatocellular Carcinoma \u2013 The Albumin-Indocyanine Green Evaluation (ALICE) Grade","volume":"11","author":"Kokudo","year":"2016","journal-title":"PLOS ONE"},{"issue":"4","key":"10.1016\/j.prp.2026.156425_bib228","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jhep.2005.12.015","article-title":"Prospective validation of the Barcelona Clinic Liver Cancer staging system","volume":"44","author":"Cillo","year":"2006","journal-title":"J. Hepatol."},{"key":"10.1016\/j.prp.2026.156425_bib229","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ejca.2016.03.002","article-title":"High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis","volume":"59","author":"Finkelmeier","year":"2016","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.prp.2026.156425_bib230","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00262-018-2271-4","article-title":"The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma","volume":"68","author":"Chang","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"issue":"2","key":"10.1016\/j.prp.2026.156425_bib231","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/SLA.0b013e318297ad6b","article-title":"Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival after hepatectomy for hepatocellular carcinoma: a retrospective analysis","volume":"258","author":"Mano","year":"2013","journal-title":"Ann. Surg."},{"issue":"8","key":"10.1016\/j.prp.2026.156425_bib232","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s00262-013-1447-1","article-title":"Increase in CD14+HLA-DR -\/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis","volume":"62","author":"Arihara","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"issue":"20","key":"10.1016\/j.prp.2026.156425_bib233","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1002\/cncr.32339","article-title":"Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma","volume":"125","author":"Feun","year":"2019","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.prp.2026.156425_bib234","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.cell.2019.10.003","article-title":"Landscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma","volume":"179","author":"Zhang","year":"2019","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib235","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/gutjnl-2015-310514","article-title":"Targeting of tumour-infiltrating macrophages via CCL2\/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma","volume":"66","author":"Li","year":"2017","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib236","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s12935-022-02771-z","article-title":"Targeted blocking of CCR2 and CXCR2 improves the efficacy of transarterial chemoembolization of hepatocarcinoma","volume":"22","author":"Tian","year":"2022","journal-title":"Cancer Cell Int"},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib237","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1053\/j.gastro.2008.03.020","article-title":"A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells","volume":"135","author":"Hoechst","year":"2008","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib238","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41421-024-00747-z","article-title":"Stromal architecture and fibroblast subpopulations with opposing effects on outcomes in hepatocellular carcinoma","volume":"11","author":"Cheng","year":"2025","journal-title":"Cell Discov."},{"key":"10.1016\/j.prp.2026.156425_bib239","doi-asserted-by":"crossref","first-page":"44","DOI":"10.22203\/eCM.v052a04","article-title":"Generation of three-dimensional (3D) breast cancer bone metastasis model for drug testing","volume":"52","author":"Nasser","year":"2025","journal-title":"Eur. Cells Mater."},{"key":"10.1016\/j.prp.2026.156425_bib240","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.actbio.2019.06.012","article-title":"In-air production of 3D co-culture tumor spheroid hydrogels for expedited drug screening","volume":"94","author":"Antunes","year":"2019","journal-title":"Acta Biomater."},{"issue":"38","key":"10.1016\/j.prp.2026.156425_bib241","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adq5226","article-title":"NF-\u03baB and TET2 promote macrophage reprogramming in hypoxia that overrides the immunosuppressive effects of the tumor microenvironment","volume":"10","author":"de la Calle-Fabregat","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.prp.2026.156425_bib242","doi-asserted-by":"crossref","first-page":"137","DOI":"10.22203\/eCM.v048a08","article-title":"Mechanical load rescues injury-induced skeletal muscle fibrosis through macrophage polarization","volume":"48","author":"Liu","year":"2024","journal-title":"Eur. Cells Mater."},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib243","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1186\/s12951-024-02567-5","volume":"22","author":"Chen","year":"2024","journal-title":"J. Nanobiotechnology"},{"issue":"8","key":"10.1016\/j.prp.2026.156425_bib244","doi-asserted-by":"crossref","first-page":"969","DOI":"10.3390\/pathogens10080969","article-title":"Monocyte infiltration and differentiation in 3D multicellular spheroid cancer models","volume":"10","author":"Madsen","year":"2021","journal-title":"Pathogens"},{"key":"10.1016\/j.prp.2026.156425_bib245","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1356144","article-title":"Evaluation of tumor response to immune checkpoint inhibitors by a 3D immunotumoroid model","volume":"15","author":"Pezeshki","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib246","article-title":"Systems biology approach to studying proliferation-dependent prognostic subnetworks in breast cancer","volume":"5","author":"Song","year":"2015","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.prp.2026.156425_bib247","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/s41575-024-01024-w","article-title":"Precision models in hepatocellular carcinoma","volume":"22","author":"Barcena-Varela","year":"2025","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.prp.2026.156425_bib248","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41598-017-00795-4","article-title":"RPI-Bind: a structure-based method for accurate identification of RNA-protein binding sites","volume":"7","author":"Luo","year":"2017","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.prp.2026.156425_bib249","doi-asserted-by":"crossref","DOI":"10.1063\/5.0057773","article-title":"In vitro 3D liver tumor microenvironment models for immune cell therapy optimization","volume":"5","author":"Lam","year":"2021","journal-title":"APL Bioeng."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033826000762?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033826000762?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:37:40Z","timestamp":1785508660000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033826000762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":249,"alternative-id":["S0344033826000762"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2026.156425","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interactions and communications in hepatocellular carcinoma: Potential targets for chemo\/radiosensitization","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2026.156425","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156425"}}